INTRODUCTION I
n the last issue of the Archive of Oncology I wrote about importance of our immune system against ovarian cancer. Maybe such a thoughts were only illusions in the past, but nowadays many laboratories worldwide examine the possibilities of our own immune system to recognize tumor cell and become active against it. Recently, another paper about a tumor infiltrating lymphocytes and their importance as a prognostic factor in endometrial cancer has been published in the Clinical Cancer Research. I would like to present this article as another important news in this field of immuno-oncology.
In developed countries, adenocarcinoma of the endometrium is the most common gynecological cancer; however, in developing countries, it is much less frequent than carcinoma of the cervix. It accounts for only 2% of all cancer-related deaths; the number of women dying of this disease is still significant (1). The median age of patients at the diagnosis of endometrial carcinoma is 63 years (2). The incidence of endometrial carcinoma is highly dependent on age; there are 12 cases per 100,000 women at 40 years of age and 84 per 100,000 at 60 (3). Seventy-five percent of women with endometrial carcinoma are postmenopausal (4). Ninety-seven percent of all cancers of the uterus arise from the glands of the endometrium and are known as endometrial carcinomas. Endometriod adenocarcinoma is the most frequent histopathologic subtype.
Christopherson et al. described adenocarcinoma, adenoacanthoma, adenosquamous carcinoma, clear-cell carcinoma, and papillary serous carcinoma, which occurred in 60%, 22%, 7%, 6%, and 5% of the cases, and found five-year survival rates of 80%, 88%, 53%, 44%, and 68%, respectively, for stage I disease (5, 6) . Ferguson et al. reported that MHC class I antigens were detected in four of eight endometrial carcinomas compared with their normal tissue counterparts (9) . Failure to express MHC class I antigens by malignant cells arises from their ability to transform and be selected during tumor progression and is thought to be an advantage of tumor resistance to attack by cytotoxic T cells (9) . Interestingly, some endometrial carcinomas express MHC class II DR antigen on the epithelial cells, suggesting that other antitumor mechanisms also play a role in the immune response (9) . Alternatively, the CTLs in endometrial carcinoma may be nonspecifically activated by a mechanism of a general inflammatory reaction, such as the release of activating cytokines (12).
In conclusion, Kondratiev's results indicate that increased numbers of TILs at the invasive border of endometrial carcinomas may be a reliable independent prognostic factor of improved patient survival. TILs in endometrial carcinoma express immunohistochemical markers of cytotoxic activity, suggesting that CTL-mediated cytotoxicity may be a key mechanism active in host versus tumor immune response. 
